Mirum Pharmaceuticals, Inc. - common stock (MIRM) analyst actions
Rating and price-target actions on MIRM in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the MIRM overview →
1 measured MIRM analyst action event.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Enthorin Therapeutics Announces Initiation of Phase II Clinical Trial of MRM-3379 (Formerly ENT-3379) for Fragile X Syndrome by Licensing Partner Mirum Pharmaceuticals | Press release | -0.27% | +1.73% |
Keep exploring
More MIRM: earnings → · SEC filings → · MIRM overview →